55 results
10-K
2023 FY
EX-10.10
FUSN
Fusion Pharmaceuticals Inc
Annual report
20 Mar 24
4:14pm
8-K
EX-10.1
FUSN
Fusion Pharmaceuticals Inc
19 Mar 24
Voting and Support Agreement
6:24am
8-K
EX-10.1
FUSN
Fusion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.2
FUSN
Fusion Pharmaceuticals Inc
11 May 23
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
7:46am
8-K
EX-10.1
vij5sz
11 May 23
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
7:46am
8-K/A
EX-10.1
ovkmy79nt8
14 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
6:11am
8-K/A
EX-10.3
8ifu4lavnoebdeb
14 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
6:11am
8-K/A
EX-10.2
7s7xd
14 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
6:11am
8-K
EX-10.3
06v3hkolrb39
13 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
5:27pm
8-K
EX-10.2
l5935s6sdxb7
13 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
5:27pm
8-K
EX-10.1
qdkihq1dcjtj7k
13 Feb 23
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
5:27pm